The 2-year results of the phase 3 PANORAMA trial evaluating intervention with aflibercept for patients with moderately severe to severe nonproliferative diabetic retinopathy showed consistent treatment greatly prevented serious vision-threatening complications and improved Diabetic Retinopathy Severity Scale scores.
Charles C. Wykoff, MD, PhD, presented the results at Bascom Palmer Eye Institute’s Angiogenesis, Exudation, and Degeneration 2020 symposium in Miami. The double-masked, randomized trial included patients with moderately severe to severe nonproliferative diabetic retinopathy
Uncategorized